Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.10−0.20 (-0.86%)
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Neurogene EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Neurogene's EPS for the twelve months ending Jun 30, 2026 was -$5.03. For fiscal 2025 it was -$4.24. The highest annual figure on record is -$3.20 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.24 | – |
| FY2024 | Dec 31, 2024 | -$4.28 | – |
| FY2022 | Dec 31, 2022 | -$5.20 | – |
| FY2021 | Dec 31, 2021 | -$5.50 | – |
| FY2020 | Dec 31, 2020 | -$3.20 | – |
| FY2019 | Dec 31, 2019 | -$12.85 | – |
| FY2018 | Dec 31, 2018 | -$6.70 | – |
| FY2017 | Dec 31, 2017 | -$10.70 | – |
| FY2016 | Dec 31, 2016 | -$9.80 | – |
| FY2015 | Dec 31, 2015 | -$8.65 | – |
| FY2014 | Dec 31, 2014 | -$13.75 | – |
| FY2013 | Dec 31, 2013 | -$247.60 | – |
| FY2012 | Dec 31, 2012 | -$201.15 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.53 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.39 | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.12 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.99 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.05 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.08 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.00 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.19 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.09 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.00 | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.67 | – |
| Q2 FY2023 | Jun 30, 2023 | -$26.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.30 | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.00 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.18 | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.40 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.40 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.38 | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.40 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.35 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.35 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.16 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.20 | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.90 | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.16 | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.30 | – |
| Q2 FY2019 | Jun 30, 2019 | $0.00 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | -$0.45 | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.04 | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.20 | – |
| Q2 FY2018 | Jun 30, 2018 | $0.60 | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.10 | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.47 | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.50 | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.95 | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.80 | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.40 | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.30 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?